Cancer Genetics reports 93% accuracy for kidney cancer test

Nano cap Cancer Genetics' (CGIX) microarray kidney cancer test delivers impressive results in a collaborative study of 188 samples with the Cleveland Clinic. The test demonstrated a sensitivity of 93% and specificity of 99%.

The company currently offers the test as a service (lab developed test or LDT).

The test is performed on kidney, either paraffin-embedded or fine needle aspirate requiring only 2 micrograms of tissue.

60,000 new cases of kidney cancer occur in the US each year with 14,000 deaths. 200,000 - 240,000 cases require annual assessment.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs